Skip to content
2000
image of Integrating Traditional Medicine with Conventional Therapies to Combat Tuberculosis: A Comprehensive Review

Abstract

Tuberculosis (TB) poses a serious public health risk and is a hot topic in the international health forums. Global health organizations emphasize the importance of effectively managing and eradicating TB. The emergence of drug-resistant TB and the elevated risk of hepatotoxicity associated with anti-TB medications have highlighted the need for reevaluation of existing TB drugs. These challenges have led to prolonged dosing schedules and increased dosages to combat resistance and effectively eliminate the disease. In India, the government revised the National Tuberculosis Control Program to address this growing concern. India is home to six well-established traditional medical systems: Ayurveda, Siddha, Unani, Yoga, Naturopathy, and Homoeopathy (collectively known as AYUSH). This review compares the effectiveness of traditional medicinal regimens with conventional TB treatment. Herbal extracts used in Ayurveda, Siddha, and Unani offer promising alternatives for TB treatment, potentially reducing hepatotoxicity and liver damage while combating antibiotic resistance. These natural remedies are generally safe for consumption in larger quantities, cost-effective to produce, and free from harmful toxins. The findings in this article provide scientific support for the anti-TB potential of the diverse medical systems recognized by India’s Ministry of AYUSH.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmm/10.2174/0115665240392305250802095145
2025-08-15
2025-11-02

  • From This Site

    /content/journals/cmm/10.2174/0115665240392305250802095145
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Yang H Ruan X Li W Xiong J Zheng Y Global, regional, and national burden of tuberculosis and attributable risk factors for 204 countries and territories, 1990–2021: A systematic analysis for the Global Burden of Diseases 2021 study BMC Public Health 2024 24 1 3111 10.1186/s12889‑024‑20664‑w 39529028
    [Google Scholar]
  2. Cowling K Dandona R Dandona L Improving the estimation of the tuberculosis burden in India Bull World Health Organ 2014 92 11 817 825 10.2471/BLT.13.129775 25378743
    [Google Scholar]
  3. Murray C.J.L. The global burden of disease study at 30 years. Nat. Med. 2022 28 10 2019 2026 10.1038/s41591‑022‑01990‑1 36216939
    [Google Scholar]
  4. Malik A.A. Khan U. Khan P. Anwar A. Salahuddin N. Khowaja S. Khan A.J. Khan S. Hussain H. Amanullah F. Drug-resistant tuberculosis treatment outcomes among children and adolescents in Karachi, Pakistan. Trop. Med. Infect. Dis. 2022 7 12 418 10.3390/tropicalmed7120418 36548673
    [Google Scholar]
  5. Bagcchi S. WHO’s global tuberculosis report 2022. Lancet Microbe 2023 4 1 20 10.1016/S2666‑5247(22)00359‑7 36521512
    [Google Scholar]
  6. Suárez I. Fünger S.M. Kröger S. Rademacher J. Fätkenheuer G. Rybniker J. The diagnosis and treatment of tuberculosis. Dtsch. Arztebl. Int. 2019 116 43 729 735 10.3238/arztebl.2019.0729 31755407
    [Google Scholar]
  7. Shah R. Khakhkhar T. Modi B. Efficacy and safety of different drug regimens for tuberculosis preventive treatment: A systematic review and meta-analysis. Cureus 2023 15 4 38182 10.7759/cureus.38182 37252497
    [Google Scholar]
  8. Yee D. Valiquette C. Pelletier M. Parisien I. Rocher I. Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am. J. Respir. Crit. Care Med. 2003 167 11 1472 1477 10.1164/rccm.200206‑626OC 12569078
    [Google Scholar]
  9. Unissa A. N. Subbian S. Hanna L. E. Selvakumar N. Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis. Infect Genet Evol 2016 45 474 492 10.1016/j.meegid.2016.09.004 27612406
    [Google Scholar]
  10. Bhanu M.L.S. Anti-tuberculosis drugs and mechanisms of action. Int. J. Infect. Dis. 2023 4 2 1 7
    [Google Scholar]
  11. Kurniawati F. Sulaiman S.A.S. Gillani S.W. Adverse drug reactions of primary anti-tuberculosis drugs among tuberculosis patients treated in chest clinic. Int J Pharm Life Sci 2012 3 1
    [Google Scholar]
  12. Tak D.K. Acharya L.D. Gowrinath K. Rao Padma G.M. Subish P. Safety evaluation of antitubercular therapy under revised national tuberculosis control programme in India. J. Clin. Diagn. Res. 2009 3 2 1395 1401
    [Google Scholar]
  13. Dedun A. Patel D. A profile of adverse effects of anti-tubercular drugs. GCSMC J Med Sci 2016 5 1 37 41
    [Google Scholar]
  14. WHO consolidated guidelines on tuberculosis. Module 4: Treatment-drug-resistant tuberculosis treatment, 2022 update. 2022 Available from: https://www.who.int/publications/i/item/9789240063129
  15. WHO consolidated guidelines on drug-resistant tuberculosis treatment (No. WHO/CDS/TB/2019.7). 2019 Available from: https://air.unimi.it/handle/2434/634426
  16. Haroon O.M. Classifying new anti-tuberculosis drugs and management of its ADR as per WHO: A short review. World J Pharm Sci 2024 12 02 1 110
    [Google Scholar]
  17. Dartois V.A. Rubin E.J. Anti-tuberculosis treatment strategies and drug development: Challenges and priorities. Nat. Rev. Microbiol. 2022 20 11 685 701 10.1038/s41579‑022‑00731‑y 35478222
    [Google Scholar]
  18. Ginsberg A.M. Spigelman M. Challenges in tuberculosis drug research and development. Nat. Med. 2007 13 3 290 294 10.1038/nm0307‑290 17342142
    [Google Scholar]
  19. Perkins M.D. O’Brien R.J. New diagnostics for tuberculosis: An essential element for global control and elimination. Reichman and Hershfield’s Tuberculosis. CRC Press 2006 1165 1184
    [Google Scholar]
  20. Samal J. Ayurvedic management of Pulmonary Tuberculosis (PTB): A systematic review. J. Intercult. Ethnopharmacol. 2016 5 1 86 91 10.5455/jice.20151107020621 27069721
    [Google Scholar]
  21. Davis L. Kuttan G. Effect of Withania somnifera on cell mediated immune responses in mice. J Exp Clin Cancer Res 2002 21 4 585 590
    [Google Scholar]
  22. Vyas P. Ghanchi F. Chandola H.M. Ranthem S. Clinical evaluation of Rasayana compound as an adjuvant in the management of tuberculosis with anti-Koch′s treatment. Ayu 2012 33 1 38 43 10.4103/0974‑8520.100307 23049182
    [Google Scholar]
  23. Dornala S. Dornala S.N. Clinical efficacy of Bhringarajasava as Naimittika Rasayana in Rajayakshma with special reference to pulmonary tuberculosis. Ayu 2012 33 4 523 529 10.4103/0974‑8520.110536 23723670
    [Google Scholar]
  24. Debnath P.K. Chattopadhyay J. Mitra A. Hazra J. Adhikari A. Alam M.S. Bandopadhyay S.K. Adjunct therapy of Ayurvedic medicine with anti tubercular drugs on the therapeutic management of pulmonary tuberculosis. J. Ayurveda Integr. Med. 2012 3 3 141 149 10.4103/0975‑9476.100180 23125511
    [Google Scholar]
  25. Mooventhan A. Khode V. Nivethitha L. Effect of yogic breathing techniques in new sputum positive pulmonary tuberculosis. Int. J. Prev. Med. 2014 5 6 787 790 25013700
    [Google Scholar]
  26. Jose S.P. M R. S S. Rajan S. Saji S. Narayanan V. S S. Anti-inflammatory effect of Kaba Sura Kudineer (AYUSH approved COVID-19 drug)-A Siddha poly-herbal formulation against lipopolysaccharide induced inflammatory response in RAW-264.7 macrophages cells. J. Ethnopharmacol. 2022 283 114738 10.1016/j.jep.2021.114738 34653521
    [Google Scholar]
  27. Rajalakshmi K. Screening of common siddha formulations for antimicrobial activity against respiratory pathogens. Asian J. Pharm. Clin. Res. 2016 267 270
    [Google Scholar]
  28. Hameed S. Hans S. Nandan S. Fatima Z. Mechanistic insights into the antimycobacterial action of unani formulation, Qurs Sartan Kafoori. J. Tradit. Complement. Med. 2022 12 2 162 171 10.1016/j.jtcme.2021.07.009 35528471
    [Google Scholar]
  29. Nikhat S. Fazil M. Overview of Covid-19; its prevention and management in the light of Unani medicine. Sci. Total Environ. 2020 728 138859 10.1016/j.scitotenv.2020.138859 32334163
    [Google Scholar]
  30. Ahmed N.Z. Agibothu Kupparam H.K. Akbar S. Hissar S. Anwar N. Thiruvengadam K. Anjum N. Khan A.A. Dar S. Natarajan S. Effects of co-administration of Unani pharmacopoeia formulations Qurs Tabasheer Sartani and Arq Hara Bhara with CAT-I antitubercular drugs in rats. J. Complement. Integr. Med. 2021 18 3 517 525 10.1515/jcim‑2020‑0262 33964191
    [Google Scholar]
  31. Ansari A.P. Anwar N. Ahmed K.K. Current status of Unani medicine in India. J Ayurv Herb Med 2024 10 3 70 72 10.31254/jahm.2024.10301
    [Google Scholar]
  32. Buranova D.D. The value of Avicenna’s heritage in development of modern integrative medicine in Uzbekistan. Integr. Med. Res. 2015 4 4 220 224 10.1016/j.imr.2015.06.002 28664128
    [Google Scholar]
  33. Packer M. Lessons for cardiovascular clinical investigators. J. Am. Coll. Cardiol. 2024 84 1 78 96 10.1016/j.jacc.2024.03.420 38925728
    [Google Scholar]
  34. Saffari M. Pakpour A.H. Avicenna’s Canon of Medicine: A look at health, public health, and environmental sanitation. Arch. Iran Med. 2012 15 12 785 789 23199255
    [Google Scholar]
  35. Charan I.A. Xin S. Zezhuang W. Yao D. Rethinking efficacy: People’s perception of ritual healing and trance religious practices at shrines in Pakistan. Asian J. Psychiatr. 2020 52 102020 10.1016/j.ajp.2020.102020 32305682
    [Google Scholar]
  36. Islam A. Origin and development of Unani medicine: An analytical study. Intellectual Discourse 2018 26 1 23 49 10.1002/9781444319996
    [Google Scholar]
  37. Quddus A. Siddiqui M. M. H. Siddiqui M. Y. Aleem S. Clinical evaluation of the efficacy of Qurs Sartan Kafoori and Sharbat Zoofa Murakkab in chronic bronchitis. Indian J Tradit Knowl 2009 8 3
    [Google Scholar]
  38. Di Stefano V. Holism and complementary medicine: Origins and principles. Routledge 2020 10.4324/9781003115984
    [Google Scholar]
  39. Chand K. S. Manchanda R. K. Mittal R. Batra S. Banavaliker J. N. De I. Homeopathic treatment in addition to standard care in multi drug resistant pulmonary tuberculosis: A randomized, double blind, placebo controlled clinical trial. Homeopathy 2014 103 2 97 107 10.1016/j.homp.2013.12.003 24685414
    [Google Scholar]
  40. WHO Traditional Medicine Strategy 2014–2023. 2025 Available from: https://apps.who.int/iris/handle/10665/92455
/content/journals/cmm/10.2174/0115665240392305250802095145
Loading
Integrating Traditional Medicine with Conventional Therapies to Combat Tuberculosis: A Comprehensive Review
Bentham Science Publishers ; https://doi.org/10.2174/0115665240392305250802095145
/content/journals/cmm/10.2174/0115665240392305250802095145
/content/journals/cmm/10.2174/0115665240392305250802095145
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Tuberculosis ; hepatotoxicity ; traditional medicine ; naturopathy ; AYUSH

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test